Ocuphire Pharma

Ocuphire to transform into gene therapy biotech via Opus buyout

Ocuphire is acquiring gene therapy developer Opus in an all-stock transaction that will see the commercial-stage company adopt the biotech’s identity.

James Waldron Oct 23, 2024 5:31am

Exscientia fires CEO—Chutes & Ladders

Feb 16, 2024 9:30am

Longtime BioMarin CEO hands off baton—Chutes & Ladders

Nov 3, 2023 9:30am

Ocuphire's diabetic eye drug misses phase 2 primary endpoint

Jan 26, 2023 8:32am